ADC Therapeutics

Yahoo Finance • 14 days ago

ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion

ADC Therapeutics S.A. (NYSE:ADCT) is one of the best performing penny stocks to buy now. On September 3 at the Cantor Global Healthcare Conference 2025, the company reiterated that it remains focused on expanding ZYNLATA’s use in DLBCL, ai... Full story

Yahoo Finance • 3 months ago

ADC Therapeutics files to sell 27.73M common shares by selling shareholders

* ADC Therapeutics (NYSE:ADCT [https://seekingalpha.com/symbol/ADCT]) filed a prospectus to sale 27.73 million shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling sharehol... Full story

Yahoo Finance • 4 months ago

ADC reports data from lymphoma trial, streamlines operations

[Business agreement] mediaphotos/iStock via Getty Images ADC Therapeutics (NYSE:ADCT [https://seekingalpha.com/symbol/ADCT]), on Thursday, reported results from an early stage trial testing its antibody drug conjugate, Zynlonta, in combin... Full story

Yahoo Finance • 2 years ago

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibiti... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics berichtet über die Finanzergebnisse des dritten Quartals 2023 und gibt aktuelle Geschäftsinformationen bekannt

Der Umsatz von ZYNLONTA®1 im 3. Quartal 2023 in Höhe von 14,3 Mio. USD spiegelt die Unterbrechung nach der Umstrukturierung der kommerziellen Organisation, den verstärkten Wettbewerb und die höheren Brutto-Netto-Abzüge wider Die Betriebsk... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics erhält Mitteilung der NYSE über Nichteinhaltung der Standards für die fortgesetzte Börsennotierung

LAUSANNE, Schweiz, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen am 10. Oktober 2023 von der New York Stock Exchange (NYSE) die Mitteilung erhalten hat, dass es die Krit... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with t... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

3Q 2023 ZYNLONTA®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23%2 year-over-yeardue to portfolio... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tu... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil

LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am Dienstag, den 14. November um 10:00 Uh... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics gibt die Annahme von Abstracts zur Präsentation auf der 65. ASH-Jahrestagung bekannt

Präsentationen zur Hervorhebung des klinischen Nutzens von ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) als Einzelwirkstoff und in Kombination Mündliche Präsentation der ersten Ergebnisse der von einem Prüfarzt initiierten Phase-II-Studie zur B... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating ZYNLONTA in combin... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics veranstaltet am 7. November 2023 eine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2023

LAUSANNE, Schweiz, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass es am Dienstag, den 7. November 2023, um 8:30 Uhr EDT eine Telefonkonferenz und einen Live-Webcast abhalten wird, um über die F... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for t... Full story

Yahoo Finance • 2 years ago

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today anno... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics nimmt im September an Anlegerkonferenzen teil

LAUSANNE, Schweiz, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass Ameet Mallik, Chief Executive Officer, im September an zwei Anlegerkonferenzen teilnehmen wird. Die Einzelheiten zu de... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics to Participate in September Investor Conferences

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September. Details of the events are... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics gibt auf der elften Jahrestagung der Society of Hematologic Oncology (SOHO 2023) Updates zu den klinischen Studienprogrammen mit ZYNLONTA® LOTIS bekannt

LOTIS-5: Aktualisierte Sicherheitsergebnisse der Phase-3-Studie zeigen eine 80%ige ORR, 50%ige CR-Rate und eine mediane DoR von 8 Monaten ohne neue Sicherheitssignale LOTIS-7: Studiendesign der Studie zur Bewertung von ZYNLONTA® bei Patie... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in patients with r/r non-Hodgkin lymphoma... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics SA: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT) investors th... Full story